Press Release | January 27, 2023
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Read More
Press Release | January 22, 2023
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Read More
Press Release | January 18, 2023
Freenome Partners with Geisinger for the Sanderson Study
Read More
Education | January 12, 2023
Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell
Read More
Press Release | January 11, 2023
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Read More
Press Release | January 9, 2023
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Read More
Press Release | January 6, 2023
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
Read More
Press Release | January 6, 2023
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
Read More
Press Release | January 5, 2023
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Read More
Press Release | January 5, 2023
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Read More
Press Release | January 5, 2023
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
Read More
News | January 4, 2023
Top Life Sciences Startups to Watch in 2023
Read More
Press Release | January 4, 2023
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
Read More
News | January 3, 2023
Viewpoint: Expanding TRIPS waiver is bad for innovation
Read More
